Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration
Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration
复制标题
DOI：
10.1007/s00417-020-05005-y
复制
发表时间：
2020-11-17
影响因子：
2.7
通讯作者：
Ohji, Masahito
中科院分区：
文献类型：
--
作者：
Sawada, Tomoko;Yasukawa, Tsutomu;Ohji, Masahito
目的我们调查了10年基线最佳矫正视力（BCVA）的变化，以及初始治疗后1年和2年的功能和解剖学变化，患有初治新生血管性年龄相关性黄斑变性（nAMD）的眼睛。方法这个回顾性的多中心病例系列回顾了2006年至2015年接受初始治疗的初治nAMD患者，使用光动力疗法（PDT）、抗血管内皮生长因子（VEGF）或PDT和抗VEGF的组合。分别于基线及随访1 ~ 2年时测量BCVA及视网膜中央亚区厚度（CRST）。基线时的平均BCVA在10年的研究期内显著改善（P < 0.001）。在2009 - 2015年接受初始治疗的患者中，1年时的BCVA较基线显著改善（P = 0.001，2009; P = 0.004，2010; P = 0.01，2011; P < 0.001，2012-2015）。在2012 - 2015年接受初始治疗的患者中，第2年BCVA较基线显著改善（P < 0.001，2012; P < 0.001，2013-2015）。从2006年到2015年，1年时的CRST较基线时的CRST显著下降（P < 0.001，2006-2015）。2006 - 2015年，基线时CRST较基线时CRST显著下降（P = 0.03，2006; P < 0.001，2007-2015）。结论初治nAMD患者基线BCVA在研究期间有改善的趋势。在抗VEGF时代，1年时的BCVA改善;在2012年或之后接受初始治疗的患者中，2年时的BCVA改善;在研究期间，CRST每年都下降。
Purpose We investigated 10-year changes in baseline best-corrected visual acuity (BCVA), as well as functional and anatomical changes at 1 and 2 years after initial treatment, in eyes with treatment-naive neovascular age-related macular degeneration (nAMD).Methods This retrospective, multicenter, case series reviewed patients with treatment-naive nAMD who underwent initial treatment from 2006 to 2015, using photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF), or a combination of PDT and anti-VEGF. BCVA and central retinal subfield thickness (CRST), were measured at baseline and at 1 or 2 years of follow-up.Results In total, 3096 eyes of 3096 patients were included from 14 hospitals. Mean BCVA at baseline became significantly better over the 10-year study period (P < 0.001). BCVA at 1 year significantly improved from baseline in patients who underwent initial treatment from 2009 to 2015 (P = 0.001, 2009; P = 0.004, 2010; P = 0.01, 2011; P < 0.001, 2012-2015). BCVA at 2 years significantly improved from baseline in patients who underwent initial treatment from 2012 to 2015 (P < 0.001, 2012; P < 0.001, 2013-2015). CRST at 1 year decreased significantly from CRST at baseline, each year from 2006 to 2015 (P < 0.001, 2006-2015). CRST at 2 years decreased significantly from CRST at baseline, each year from 2006 to 2015 (P = 0.03, 2006; P < 0.001, 2007-2015).Conclusion Baseline BCVA with treatment-naive nAMD tended to become better during the study period. BCVA at 1 year improved in the era of anti-VEGF; BCVA at 2 years improved in patients who underwent initial treatment in 2012 or later; and CRST decreased in each year during the study period.